Rafferty Asset Management LLC Has $404,000 Stock Position in Celcuity Inc. (NASDAQ:CELC)

Rafferty Asset Management LLC lowered its holdings in shares of Celcuity Inc. (NASDAQ:CELC - Free Report) by 45.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,878 shares of the company's stock after selling 25,709 shares during the period. Rafferty Asset Management LLC owned about 0.08% of Celcuity worth $404,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Nuveen Asset Management LLC boosted its stake in Celcuity by 10.8% during the fourth quarter. Nuveen Asset Management LLC now owns 69,587 shares of the company's stock worth $911,000 after buying an additional 6,785 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Celcuity by 16.2% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,725 shares of the company's stock worth $258,000 after buying an additional 2,756 shares in the last quarter. J. Goldman & Co LP acquired a new stake in Celcuity during the fourth quarter worth $567,000. Janus Henderson Group PLC acquired a new stake in Celcuity during the fourth quarter worth $8,468,000. Finally, Deutsche Bank AG boosted its stake in Celcuity by 67.1% during the fourth quarter. Deutsche Bank AG now owns 22,842 shares of the company's stock worth $299,000 after buying an additional 9,174 shares in the last quarter. Institutional investors and hedge funds own 63.33% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Needham & Company LLC reiterated a "buy" rating and set a $29.00 price target on shares of Celcuity in a research note on Thursday, May 15th. HC Wainwright reiterated a "buy" rating and set a $27.00 price target on shares of Celcuity in a research note on Monday, May 19th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $30.80.

Celcuity Price Performance

Shares of NASDAQ:CELC traded up $0.29 on Thursday, hitting $10.79. The stock had a trading volume of 12,669 shares, compared to its average volume of 297,553. Celcuity Inc. has a twelve month low of $7.58 and a twelve month high of $19.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The firm's 50 day moving average price is $10.19 and its 200-day moving average price is $11.42. The company has a market capitalization of $408.38 million, a price-to-earnings ratio of -4.13 and a beta of 0.56.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.09. On average, equities research analysts predict that Celcuity Inc. will post -2.62 earnings per share for the current year.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.